 The combination of weekly paclitaxel and pazopanib is feasible and the dose proposed for further phase 2 studies is pazopanib 800 mg daily and paclitaxel 65 mgm2 at day 1, 8, 15 every 28 days Tan, the oncologist 2010. The dosage of paclitaxel was justified on results from previous studies, demonstrating that co-administration of pazopanib and paclitaxel increases the systemic exposure to paclitaxel. An Italian group has just closed a phase 2 study MITO11 that evaluated this association among ovarian patients with early relapse. In this study, patients did not receive previously bevacizumab. 